drugset / Trial / NCT03413384
To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
Phase 2
Active not recruiting
100 enrolled
BrainX Corporation
Virginia Contract Research Organization Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double blinded, placebo-controlled Phase II study to investigate the efficacy and safety of ceftriaxone in patients with mild to moderate Parkinson's disease dementia (PDD).This study will enroll approximately 106 patients to have up to 84 evaluable subjects, and conduct in Chung Shan Medical University Hospital, National Taiwan University Hospital, Kaohsiung Chang Gung Memorial Hospital, China Medical University Hospital, Changhua Christian Hospital, and Taipei Veterans General Hospital.
Timeline
- Start
- 2019-02-15
- Primary completion
- 2025-07-28
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceftriaxone | Other / unclassified | 1 g | Intramuscular |